A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/1/2014 |
| Start Date: | April 2012 |
| End Date: | September 2015 |
| Contact: | Synta Pharmaceuticals clinicaltrials.gov call center |
| Email: | 9090-09_StudyInfo@syntapharma.com |
| Phone: | 855 499-9664 |
A Single Arm, Phase 2 Study of Ganetespib in Subjects With Advanced Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior
therapies. The study will take place globally at multiple study centers. Subjects will be
enrolled to receive ganetespib one time per week for three weeks followed by a rest week;
and will repeat this schedule until the cancer gets worse or the subject is unable to
tolerate ganetespib. The primary goal of the study is to determine how ganetespib is
tolerated and how active it is in ALK positive NSCLC.
therapies. The study will take place globally at multiple study centers. Subjects will be
enrolled to receive ganetespib one time per week for three weeks followed by a rest week;
and will repeat this schedule until the cancer gets worse or the subject is unable to
tolerate ganetespib. The primary goal of the study is to determine how ganetespib is
tolerated and how active it is in ALK positive NSCLC.
Inclusion Criteria:
- Males or females aged 18 years or older
- Pathological confirmation of advanced NSCLC
- Evidence of a translocation or an inversion event involving the ALK gene locus
- ECOG Performance Status 0 or 1
Exclusion Criteria:
- Prior therapy with ALK-targeted agents
- Prior treatment with Hsp90 inhibitor
- Known EGFR activating mutation
- Presence of active or untreated central nervous system (CNS) metastases
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials